NOVATARG THERANOSTICS, INC
Summary
Pioneering, proprietary and patented, Two-Dimensional Long-Range Ordering and Clustering, (2D L-ROC) platform, rapid, accurate, label-free COVID-19 antibody testing, COVID-19 antigen testing, structure-based COVID-19 therapeutic, Structure-based COVID-19 vaccine, high-sensitivity functional screening, high-sensitivity molecular imaging, membrane protein, ACE2, SARS-CoV-2, spike (S) glycoprotein, envelope(E)protein, membrane (M) protein, Surface Plasmon Resonance (SPR)
Profile
Address
Description
NOVATARG Theranostics proposes sole source small business innovation research (SBIR) projects to deploy its pioneering, proprietary and patented Two-Dimensional Long-Range Ordering and Clustering (2D L-ROC) platform, to enable (1) rapid, accurate, label-free COVID-19 antibody and antigen testing, and (2) structure-based, COVID-19 therapeutic and vaccine interventions. NOVATARG’s advances have the potential to accelerate the U.S. readiness to COVID-19 and other future viral threats for which no effective interventions exist.
Contact
Special Details
Similar Listings
Pagination
- Page 1
- Next page